menu
    • menu
    [{"orgOrder":0,"company":"Advicenne","sponsor":"FrostPharma AB","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Advicenne \/ FrostPharma AB","highestDevelopmentStatusID":"15","companyTruncated":"Advicenne \/ FrostPharma AB"},{"orgOrder":0,"company":"Advicenne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Advicenne \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advicenne \/ Inapplicable"},{"orgOrder":0,"company":"Advicenne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Advicenne \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advicenne \/ Inapplicable"},{"orgOrder":0,"company":"Advicenne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Advicenne \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advicenne \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Advicenne

    Menu

    Advicenne

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Advicenne

    France arrow
    Interphex
    Not Confirmed

    Advicenne

    France arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

    Therapeutic Area : Nephrology

    Study Phase : Approved FDF

    Sponsor : FrostPharma AB

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Advicenne Announces Commercialization Agreement With FrostPharma AB for Sibnayal™ in the Nordic region

    Details : Under the terms of the agreement, FrostPharma will receive exclusive marketing rights to Sibnayal™ for the treatment of dRTA. Advicenne will receive a transfer price for the sale of its product and royalties for an amount significantly higher than 50% ...

    Product Name : Sibnayal

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    April 01, 2022

    Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

    Therapeutic Area : Nephrology

    Highest Development Status : Approved FDF

    Sponsor : FrostPharma AB

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Advicenne

    France arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Advicenne

    France arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

    Therapeutic Area : Nephrology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Advicenne Receives Positive Feedback from the US FDA on Phase III Study Protocol for its Treatment of dRTA

    Details : Advicenne’s lead product, ADV7103, is developed as a multi-particulate formulation in 2mm microtablets, a novel pioneering delivery technology created by Advicenne that contains two active pharmaceutical ingredients to ease its administration.

    Product Name : Sibnayal

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    May 17, 2021

    Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

    Therapeutic Area : Nephrology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Advicenne

    France arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Advicenne

    France arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

    Therapeutic Area : Nephrology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Advicenne Receives European Commission Approval to Market ADV7103 (Sibnayal™) and announces Leadership Chang...

    Details : ADV7103/Sibnayal (potassium citrate) becomes the first and only label-approved drug for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older.

    Product Name : Sibnayal

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    March 05, 2021

    Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

    Therapeutic Area : Nephrology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Advicenne

    France arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Advicenne

    France arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

    Therapeutic Area : Nephrology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of DRTA

    Details : Sibnayal™ is a multi-particulate formulation in 2mm granules, a novel pioneering delivery technology created by Advicenne that contains two active pharmaceutical ingredients.

    Product Name : Sibnayal

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 07, 2021

    Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

    Therapeutic Area : Nephrology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth